

The gRNA-miRNA-gRNA ternary cassette combining CRISPR/Cas9 with
RNAi approach strongly inhibits hepatitis B virus replication

Jie Wang^{1†}, Ran Chen^{1†}, Ruiyang Zhang^{1†}, Shanlong Ding¹, Tianying Zhang², Quan Yuan², Guiwen Guan¹, Xiangmei Chen¹, Ting Zhang¹, Hui Zhuang¹, Frederick Nunes³, Timothy Block⁴, Shuang Liu⁵, Zhongping Duan⁵, Ningshao Xia^{2*}, Zhongwei Xu^{3*}, Fengmin Lu^{1*}

Supplementary materials

Table S1. Oligo-nucleotides sequences for constructing gRNA-miR-HBV-gRNA cassette

Name	Sequences
Pri-miR-31(22+21)/miR-HBV	Top: 5'-TCGAGctgttaactcggaactggagaggGGTGAAGCGAAGTGCACACGGgttgaactggaaacgACGTGTGCACATCGATTCACGGCttccgtctgacagcagcttG-3' Bottom: 5'-GATCCAagctgctgtcagacaggaaaGCCGTGAATCGATGTGCAACACGTcggtcccagtcaacCCGTGTGCACTTCGCTTCACCcctctccagttccgatcacagC-3'
Pri-miR-31(30+31)/miR-HBV	Top: 5'-TCGAGtattgtccctgttaactcggaactggagaggGGTGAAGCGAAGTGCACACGGgttgaactggaaacgACGTGTGCACATCGATTCACGGCttccgtctgacagcagctggctacctccG-3' Bottom: 5'-GATCCggaggtagccaagctgctgtcagacaggaaaGCCGTGAA TCGATGTGCACACGTcggtcccagtcaacCCGTGTGCACTTCGCTTCACCcctctccagttccgatcacagcaataC-3'
gRNA3	Top:5'-CACCGCAAGCCTCCAAGCTGTGCCT-3' Bottom:5'-AACACAGGCACAGCTTGGAGGCTTGC-3'
gRNA4	Top: 5'-CACCGCGAGGGAGTTCTTCTTAG-3'

Bottom: 5'-AACCTAGAAGAAGAACTCCCTCGC-3'

Table S2. The synthesized gene sequences for constructing gRNA-miR-HBV-gRNA ternary cassette and gRNA-gRNA binary cassette

Name	Sequences
Pri-miR-31(38+40)/miR-HBV	5'-agaCTCGAGaggatggattgctctgttaactcggaactggagaggGGTG AAGCGAAGTGCACACGGgttgaactggaaacgACGTGTGCACATCG ATTCACGGCttccctgtctgacagcagctggctacccgcctgttcGGATCCgag- 3'
Pri-miR-31(38+40)/miR-HBVm	5'-agaCTCGAGaggatggattgctctgttaactcggaactggagaggGGTG AAGCGAATGGCATAGCGgttgaactggaaacgAGCTATGCCACATC GATTCACGGCttccctgtctgacagcagctggctacccgcctgttcGGATCCgag- 3' 5'-agaCTCGAGcataacaacgaagaggatggattgctctgttaactcggaact
Pri-miR-31(51+51)/miR-HBV-gRNA1	ggagaggGGTAAGCGAAGTGCACACGGgttgaactggaaacgACGTG TGCACATCGATTACGGCttccctgtctgacagcagctggctacccgcctgttc ctcctgtcttGGATCCgagCCTGCTGGCTCCAGTCGTTTAGA GCTAGAAATAGCAAGTAAAATAAGGCTAGTCCGTTATCAA CTTGAAAAAGTGGCACCGAGTCGGTGCTttttaccAAGCTTgca-3'
Pri-miR-31(51+51)/miR-HBV-gRNA2	5'-agaCTCGAGcataacaacgaagaggatggattgctctgttaactcggaact ggagaggGGTAAGCGAAGTGCACACGGgttgaactggaaacgACGTG TGCACATCGATTACGGCttccctgtctgacagcagctggctacccgcctgttc ctcctgtcttGGATCCgagGGTGCGTCAGCAAACACTGTTTAGA GCTAGAAATAGCAAGTAAAATAAGGCTAGTCCGTTATCAA CTTGAAAAAGTGGCACCGAGTCGGTGCTttttaccAAGCTTgca-3'
U6-gRNA2	5'-agaCTCGAGttttgaggccatattccatgattcctcatattgcatatacgata caaggcttagagagataatttgaattttactgtaaacacaaaagatattgtacaaaatacgtg acgtagaaagtaataattcttggtagttgcagttaaaattatgtttaaaatggactatcatatgctt accgttaactgaaagtatttcgatttcttggcttatatatcttGTGGAAAGGACGAAAC ACCGGTTGCGTCAGCAAACACTGTTTAGAGCTAGAAATAG

CAAGTTAAAATAAGGCTAGTCGTTATCAACTTGAAAAAGT
GGCACCGAGTCGGTGttttaccAAGCTTgca-3'

Table S3. Target sequences of the HBV-specific gRNAs in HBV genome

gRNA No.	Sequence (N ₁₉₋₂₀ NGG, 5'-3')	Genotype
1	CCTGCTGGTGGCTCCAGTTC	A/B/C/D
2	AGTGTGCTGACGCAACC	A/B/C/D
3	CAAGCCTCCAAGCTGTGCCT	A/B/C/D
4	CTAGAAGAAGAACTCCCTCG	A/B/C/D

Table S4. The full DNA sequences of all gRNAa-miR-HBV-gRNAb cassettes

Name	Sequences
3-H51-2	5'- GCAAGCCTCCAAGCTGTGCCT GTAGAGCTAGAAATAGCAAG TTAAAATAAGGCTAGTCGTTATCAACTTGAAAAAGTGGCACCG AGTCGGTGC CTCGAG cataacaacgaagaggatggattgcctgtactcgaaactgg agagg GGTGAAGCGAACGTGCACACGG gttgaactggaaacg ACGTGTGCA CATCGATTACCGGC tttcctgtctgacagcagctggctacccgtcctgtccctgtt G GATCC gag GGTTGCGTCAGCAAACACT GTAGAGCTAGAAATA GCAAGTTAAAATAAGGCTAGTCGTTATCAACTTGAAAAAGTGG CACCGAGTCGGTGC tttttaccAAGCTT-3'
3-H38-2	5'- GCAAGCCTCCAAGCTGTGCCT GTAGAGCTAGAAATAGCAAG TTAAAATAAGGCTAGTCGTTATCAACTTGAAAAAGTGGCACCG AGTCGGTGC CTCGAG aggatggattgcctgtactcgaaactggagg GGTGA AGCGAACGTGCACACGG gttgaactggaaacg ACGTGTGCA ATCGATT ACGGC tttcctgtctgacagcagctggctacccgtcctgtt GGATCC gag GGTTGCG TCAGCAAACACT GTAGAGCTAGAAATAGCAAGTTAAAATA GGCTAGTCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC t tttttaccAAGCTT-3'

5'-**GCAAGCCTCCAAGCTGTGCCT**GT~~TTT~~AGAGCTAGAAATAGCAAG
T~~AAA~~AATAAGGCTAGTCCGTATCAACTTGAAAAAGTGGCACCG
AGTCGGT**GCCTCGAGG**aggatggattgtcctgtaactcggaactggagagg**GGTG**
AAGCGAATGGCATAGCGgttgaactggaaacg**AGCTATGCCAATCGATT**
CACGGCt~~tt~~c~~t~~gtc~~t~~gacagcagcttg~~gt~~ac~~c~~c~~g~~t~~c~~gttc**GGATCC**gag**GGTG**
GTCAGCAAACACTGT~~TTT~~AGAGCTAGAAATAGCAAGT~~AAA~~ATA
AGGCTAGTCCGTATCAACTTGAAAAAGTGGCACCGAGTCGGT**GC**
Ct~~tttt~~accAAGCTT-3'

5'-**GCAAGCCTCCAAGCTGTGCCT**GT~~TTT~~AGAGCTAGAAATAGCAAG
T~~AAA~~AATAAGGCTAGTCCGTATCAACTTGAAAAAGTGGCACCG
AGTCGGT**GCCTCGAG**tattgtcctgtaactcggaactggagagg**GGTGAAGCGA**
AGTGCACACGGgttgaactggaaacg**ACGTGTGCACATCGATT**CACGGC**tt**
tcctgctgacagcagcttg~~gt~~ac~~c~~c~~g~~t~~c~~cc**GGATCC**gag**GGTGCGTCAGCAAACAC**
TGT~~TTT~~AGAGCTAGAAATAGCAAGT~~AAA~~ATAAGGCTAGTCGGT
TATCAACTTGAAAAAGTGGCACCGAGTCGGT**GC**t~~tttt~~accAAGCTT-3'

5'-**GCAAGCCTCCAAGCTGTGCCT**GT~~TTT~~AGAGCTAGAAATAGCAAG
T~~AAA~~AATAAGGCTAGTCCGTATCAACTTGAAAAAGTGGCACCG
AGTCGGT**GCCTCGAG**ct~~gt~~aactcggaactggagagg**GGTGAAGCGAAGTG**
CACACGGgttgaactggaaacg**ACGTGTGCACATCGATT**CACGGC**tt**~~c~~c~~t~~g~~t~~c
~~t~~gacagcag**tt****GGATCC**gag**GGTGCGTCAGCAAACACT**GT~~TTT~~AGAG
CTAGAAATAGCAAGT~~AAA~~ATAAGGCTAGTCGGTATCAACTTG
AAAAAGTGGCACCGAGTCGGT**GC**t~~tttt~~accAAGCTT-3'

5'-**GCGAGGGAGTTCTCTTAG**GT~~TTT~~AGAGCTAGAAATAGCAAG
T~~AAA~~AATAAGGCTAGTCCGTATCAACTTGAAAAAGTGGCACCG
AGTCGGT**GCCTCGAG**aggatggattgtcctgtaactcggaactggagagg**GGTGA**
AGCGAAGTGCACACGGgttgaactggaaacg**ACGTGTGCACATCGATT**C
ACGGCt~~tt~~c~~t~~g~~t~~c~~g~~acagcagcttg~~gt~~ac~~c~~c~~g~~t~~c~~tt**GGATCC**gag**CCTG**
GT~~GG~~C~~T~~CCAGTC~~G~~T~~TT~~AGAGCTAGAAATAGCAAGT~~AAA~~ATA
AGGCTAGTCCGTATCAACTTGAAAAAGTGGCACCGAGTCGGT**GC**
Ct~~tttt~~accAAGCTT-3'

The red letters were the sequences of gRNA, the sequences of HBV specific short guide RNA were highlighted in green for gRNAa and in yellow for gRNAb; The blue letters were the sequences of pri-miR31 and anti-HBV pri-miR-31 mimic, the sequences of miRNA were highlighted in dark blue; The sequences of XhoI and HindIII restriction endonucleases cutting sites were shown in bold fonts.




Figure S1. A dual-luciferase assay was conducted to analyze the level of miR-HBV produced by 4-H38-1 cassette. pGL3-HBV (1575-1604), PRL-TK and the expression plasmid containing 4-H38-1 cassette were co-transfected into HuH7 cells, and the dual-luciferase assay was performed. Data was shown as mean±SD of 5 independent experiments.




Figure S2. The cytotoxicity of 3-2 binary and gRNA-miR-HBV-gRNA ternary cassettes was examined using an MTT assay. Data was shown as mean±s.e.m. of 5 independent experiments.




Figure S3. The HBV-specific gRNAs-mediated destructions of HBV genome were detected by Southern Blot. (A) Schematic illustration of Cas9/gRNA-mediated destruction of HBV genome (1.3xHBV expression plasmid). (B) The Cas9/gRNA-mediated destructions of HBV genome (1.3xHBV expression plasmid) were detected by Southern Blot. Vector group is the PX458 plasmid (the backbone of 3-2 and 3-H38-2 expression plasmid) was contranfected with pGEM-HBV1.3A or pGEM-HBV1.3B into HuH7 cells.